Posted August 17, 2018
Thanks to a $300 million payout to 23andMe, GlaxoSmithKline will soon have access to hundreds of thousands of people’s DNA. And there’s one reason: money. “On Wednesday, the genetic testing company announced it was entering a partnership with pharmaceutical giant GlaxoSmithKline (GSK) to develop new drugs and therapies. As part of the collaboration, the company will allow GSK to peek at the (voluntarily shared) genetic data of millions of people who have taken 23andMe’s DNA home testing kits.” Read more.